САХАРИД-КОНЪЮГАТНЫЕ ВАКЦИНЫ

Изобретение раскрывает композиции для вызывания иммунного ответа у пациента, включающие комбинацию двух или более моновалентных конъюгатов, где каждый из моновалентных конъюгатов включает протеин-носитель N19, конъюгированный с сахаридным антигеном из серогрупп А, С, W135 или Y Neissera meningitides. При этом предпочтительно, что молекула протеина-носителя в моновалентном конъюгате конъюгирована более чем с одной молекулой сахаридного антигена. Изобретение также раскрывает мультивалентный конъюгат для вызывания иммунного ответа у пациента, включающий два или более антигенно отличающихся сахаридных антигенов из серогрупп А, С, W135 или Y Neissera meningitides, конъюгированных с протеином-носителем N19. Композиции могут включать один или более упомянутых моновалентных конъюгатов и один или более упомянутых мультивалентных конъюгатов. В изобретении показана возможность применения мультивалентного конъюгата и композиций в производстве медикамента для усиления иммунного ответа у пациента. Композиции ...

МОДИФИЦИРОВАННЫЙ БИОТИН-СВЯЗЫВАЮЩИЙ БЕЛОК, СЛИТЫЕ БЕЛКИ НА ЕГО ОСНОВЕ И ИХ ПРИМЕНЕНИЕ

Изобретение относится к области биотехнологии, конкретно к получению модифицированных биотин-связывающих белков, и может быть использовано в медицине для индуцирования иммунного ответа против антигенного белка или пептида. Получают слитый биотин-связывающий белок, который включает растворимый биотин-связывающий белок и антигенный белок или пептид, причем слитый белок не включает аминокислоты 1-44 белка Ризавидина дикого типа. Изобретение позволяет экспрессировать слитые биотин-связывающие белки в E. coli в растворимой форме и с высоким выходом, а также повысить эффективность образования комплексов биотин-связывающих белков и белковых антигенов. 2 н. и 16 з.п. ф-лы, 14 ил., 5 табл., 7 пр.

Покрытые онколитические аденовирусы для пртивораковых вакцин

HIV-1- UND HIV-2-PEPTIDE ZUR INHIBITION VON MIT MEMBRANFUSIONEN IN ZUSAMMENHANG STEHENDEN PHÄNOMENEN, EINSCHLIESSLICH DER ÜBERTRAGUNG VON HIV

Process for preparing vaccine composition

Process for preparing vaccine composition

IMMUNE ANSWER AGAINST HPV OF ANTIGENS CAUSED OF COMPOSITIONS SOME HPV ANTIGEN AND A STRESS PROTEIN CONTAINING OR AN EXPRESS ION VECTOR ABLE OF EXPRESSION THESE PROTEINS

GERINNUNGSFAKTOR FC CHIMERE OF PROTEINS FOR THE TREATMENT OF HÄMOPHILIE

ENTZÜNDUNGSHEMMENDE FETTALKOHOLE AND FATTY ACID ESTERS AS ANTIGEN CARRIERS

IMMUNSTIMULATORI COMPOSITIONS AND PROCEDURES FOR THE STIMULATION OF AN IMMUNE ANSWER

COMPOSITION WITH IMMUNOGEN MICRO PARTICLES

IL-1-ALPHA FOR THE EMPLOYMENT IN A PROCEDURE FOR THE TREATMENT OF ATHEROSKLEROTI PLAQUES.

LOCK VIRUS VACCINE.

IMMUNE-STIMULATING COMPOSITIONS THE ONE A MINERAL SALT AND A FURTHER CONTAINING ADJUVANT

ANTIGEN ABSTENTION MICRO PARTICLE AND YOUR USE FOR INDUCING OF HUMORALEN OR CELLULAR ONE ANSWERS

ORAL DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES BOUND TO VITAMIN B12, OR ANALOGUES THEREOF

Precision glycoconjugates as therapeutic tools

The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resulting antibodies. Improved methods of more directly and precisely conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including "click-chemistry" approaches based on photocatalytic thiol-ene reactions.

Clotting factor-Fc chimeric proteins to treat hemophilia

Vaccine nanotechnology

Multivalent synthetic nanocarrier vaccines

The invention relates, at least in part, to compositions comprising population of synthetic nanocarries that comprise different sets of antigens as well as related methods.

Immunogenic CD91 ligand-antigenic molecule complexes and fusion proteins

Human Immunodeficiency Virus Envelope Glycoprotein Mutants and Uses Thereof

Immunostimulatory compositions and methods of stimulating an immune response

Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom

... 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.

VIRAL DECOY VACCINE

Immunogenic construct comprising an EBV-cell antigen and a targeting moiety and applications thereof

The present invention generally relates to an immunogenic construct,useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism,to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Vaccine containing immobilized virus particles

The present invention relates to a vaccine containing immobilized virus particles, wherein the sum total of exothermic reactions in three rabbits in an exothermic test on the immobilized virus particles is less than 80% relative to the sum total of exothermic reactions in three rabbits in the exothermic test on virus particles from which the immobilized virus particles are originated or inactivated virus particles which correspond to the immobilized virus particles.

OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS

This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use. See Fig. 2. WO 2012/135010 PCT/US2012/030314 45% *n 44~ 35% .. o 30% 4-1 20% 15% 0 S10% -'5% 0% 0 100 200 300 400 Calculated Osmolality (mOsm/kg) Fig. 1 Release Medium Osmolality (mOsm/kg) Fig. 2 ...

HIV EPITOPES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS

The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

VACCINE NANOTECHNOLOGY

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

ORAL DELIVERY SYSTEM

ORAL DELIVERY SYSTEMS The present invention provides a complex of a drug, hormone, bio-active peptide, or immunogen with the carrier molecule vitamin B12 and a method for delivering said complex to the intestine of a host vertebrate in order to deliver the complex to the circulation of the host and thereby elicit a pharmacological response to the drug, hormone, or bio-active molecule or to elicit a systemic immune response to the immunogen. The invention also provides a method for the production of the complex. Further the invention provides medicaments containing the complex.

NEW SWINE INFLUENZA VACCINE

The present invention relates i.a. to EHV vector's comprising at least one (at least two) exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, said exogenous antigen encoding sequence is inserted into an insertion site (preferably ORF70) and said exogenous antigen encoding sequence is operably linked to a promoter sequence (preferably promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof). Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal of need.

IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS

The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration a or are exclusively in anomeric configuration ß and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.

COMPOSITIONS AND METHODS FOR IMMUNODOMINANT ANTIGENS

Contemplated compositions, devices, and methods comprise immunodominant a ntigens from selected human pathogens (Burkholderia pseudomallei, Borrelia b urgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Fra ncisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diag nostic markers, and as therapeutic agents. In particularly preferred aspects , the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known associa tion with a disease parameter.

COMPOSITIONS AND METHODS FOR IMMUNODOMINANT ANTIGENS

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis,Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

OPTIMAL POLYVALENT VACCINE FOR CANCER

This invention provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of : a) selection of an appropriate cancer cell line; and b) detection of the expression of antigens on the surface of said cell line of the cancer, wherein the antigens expressed will be used in the polyvalent vaccine. This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of : a) selection of an appropriate cancer cell line and b) detection of the immunogenicity will be used in the polyvalent vaccine. This invention provides various uses of the identified polyvalent vaccine.

DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF

Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.

VIRAL DECOY VACCINE

A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When viral protein is attached to the core particles, the result is a viral decoy which accurately mimics the native virus in both size and structure while being entirely devoid of virulent activity due to the microparticle core. Other antigenic proteins or peptides are attached to provide molecules which are useful in raising antibodies or as a diagnostic tool. Further, pharmacological agents are attached to the microparticles to provide pharmaceutical compositions. The viral decoys are useful as vaccines for treating animals to elicit an immune response.

VIRAL DECOY VACCINE

A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When viral protein is attached to the core particles, the result is a viral decoy which accurately mimics the native virus in both size and structure while being entirely devoid of virulent activity due to the microparticle core. Other antigenic proteins or peptides are attached to provide molecules which are useful in raising antibodies or as a diagnostic tool. Further, pharmacological agents are attached to the microparticles to provide pharmaceutical compositions. The viral decoys are useful as vaccines for treating animals to elicit an immune response.

METHODS AND COMPOSITIONS FOR TREATING SYNTHETIC NANONOSITELYaMI AND INHIBITORS OF IMMUNE CONTROL POINT OF

ВАКЦИНА

Компонент для вакцины против ВИЧ или жидкий нефасованный препарат, содержащий: а) иммуногенный слитый белок, содержащий Nef или его иммуногенный(ое) фрагмент или производное и р17 Gag и/или р24 Gag или их иммуногенные фрагменты или производные, причем когда присутствуют оба р17 и р24 Gag, тогда между ними находится по меньшей мере один антиген или иммуногенный фрагмент ВИЧ, и б) стабилизирующий агент, выбранный из группы, содержащей или состоящей из монотиоглицерина, цистеина, N-ацетилцистеина или их смесей. Изобретение также охватывает вакцины против ВИЧ, содержащие указанный компонент для вакцины против ВИЧ или жидкий нефасованный препарат, и применение в лечении/предупреждении ВИЧ.

ВЕКТОРЫ И КОНСТРУКЦИИ ДЛЯ ДОСТАВКИ ГРИППОЗНОГО АНТИГЕНА

Настоящее изобретение относится к фторуглеродным векторам для доставки гриппозных антигенов к иммунологически реактивным клеткам-мишеням. Кроме того, изобретение относится к конструкциям "вектор-гриппозный антиген" и к применению указанных векторов, связанных с антигенами, в качестве вакцин и иммунотерапевтических агентов у животных, включая людей.

VACCINE AGAINST HEPATITIS B VIRUS

用作抗原载体的抗炎性脂肪醇和脂肪酸酯

... 本发明提供用于治疗T细胞介导性疾病的治疗性制剂，其包含抗原和载体，其中所述抗原被与所述T细胞介导性疾病发病相关的炎性T细胞识别，而其中所述载体为选自以下的抗炎免疫调节剂：(a)饱和或顺式不饱和C#-[10]-C#-[20]脂肪醇或其与C#-[1]-C#-[6]链烷酸的酯；和(b)饱和或顺式不饱和C#-[10]-C#-[20]脂肪酸酯，其选自脂肪酸的C#-[1]-C#-[6]烷基酯、脂肪酸与具有至少两个羟基的C#-[2]-C#-[6]多元醇的单酯以及脂肪酸与甘油的二酯。 ...

Microparticles carrying of the antigens and their use for induction of answers humorales or cellular.

Nanoparticle-Peptide Compositions

New EHV insertion site ORF70

The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site ORF70. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS

Immunostimulatory oligonucleotides

Disclosed herein are immunostimulatory oligonucleotides and compositions and methods of use thereof. More specifically, immunostimulatory oligonucleotides, methods of optimizing the immunostimulatory properties of oligonucleotides, and methods of using the immunostimulatory oligonucleotides to elicit a toll-like receptor 21 (TLR21)-mediated immune response are disclosed.

COMPOSITIONS AND METHODS INVOLVING O-ACETYLATED GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDES

The present invention provides compositions related to purified group B Streptococcus capsular polysaccharides with O-acetylated N-acetylneuraminic acid residues and methods of using these compositions for generating immunity to group B Streptococcus bacterium in subjects.

ORAL DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES BOUND TO VITAMIN B12, OR ANALOGUES THEREOF

Complex of a drug, hormone, bio-active peptide, or immunogen with the carrier molecule vitamin B12 and a method for delivering said complex to the intestine of a host vertebrate in order to deliver the complex to the circulation of the host and thereby elicit a pharmacological response to the drug, hormone, or bio-active molecule or to elicit a systemic immune response to the immunogen. The invention also provides a method for the production of the complex. Further the invention provides medicaments containing the complex.

MODIFIED ADENOVIRUSES FOR CANCER VACCINES DEVELOPMENT

The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.

Antigen delivery vectors and constructs

The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

VACCINE DELIVERY SYSTEMS USING YEAST CELL WALL PARTICLES

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

COMPOSITIONS COMPRISING SECRETED EXTRACELLULAR VESICLES OF CELLS EXPRESSING NFATC4 USEFUL FOR THE TREATMENT OF CANCER

The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGFβ1 expression level.

CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA

СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА И СВЯЗАННЫХ С НИМ ЗАБОЛЕВАНИЙ

Изобретение относится к области биотехнологии, конкретно к комплексу антиген-МНС-наночастицы, где антигеном является связанный с рассеянным склерозом антиген, и может быть использовано в медицине. Комплекс антиген-МНС-наночастицы может быть использован в способе экспансии популяций противовоспалительных аутореактивных T-клеток у лиц с рассеянным склерозом, включающем введение данному лицу эффективного количества комплекса антиген-МНС-наночастицы. 4 н. и 8 з.п. ф-лы, 21 ил., 3 табл., 5 пр.

АНТИГЕННЫЕ КОМПОЗИЦИИ РЕСПИРАТОРНОГО СИНЦИТИАЛЬНОГО ВИРУСА И СПОСОБЫ

Настоящее изобретение относится к области биотехнологии. Предложены иммуногенные композиции в виде многослойной пленки, содержащей В-клеточный (антительный) эпитоп RSV-Gи дополнительно Т-клеточный эпитоп RSV-M2белков респираторного синцитиального вируса (RSV), причем эпитоп RSV-G находится во внешнем слое пленки. Указанная пленка содержит два или более слоя полиэлектролитов, где смежные слои содержат противоположно заряженные полиэлектролиты, содержащие поликатионное вещество или полианионное вещество, имеющее молекулярную массу, превышающую 1000, и по меньшей мере 5 зарядов на молекулу. В дополнение описан способ иммунизации против RSV. Композиции по настоящему изобретению обеспечивают увеличенный В-клеточный ответ против RSV и могут найти применение в профилактике инфекции RSV. 3 н. и 14 з.п. ф-лы, 21 ил., 5 табл., 19 пр.

СОСТАВЫ ВАКЦИН ПРОТИВ НЕОПЛАЗИИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

ВАКЦИНА TSLP ДЛЯ ЛЕЧЕНИЯ ТН2-ОПОСРЕДОВАННЫХ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ

... 1. Вакцина, содержащая TSLP (тимусный стромальный лимфопоэтин) или по меньшей мере один его фрагмент от примата, не являющегося человеком, или от другого млекопитающего, не являющегося человеком, и фармацевтически приемлемые адъюванты. ! 2. Вакцина по п.1, где по меньшей мере один фрагмент TSLP в его исходной или мультимеризованной форме связан с молекулой-носителем. ! 3. Вакцина по п.1 или 2, где TSLP представляет собой TSLP примата, не являющегося человеком, собаки, кошки или лошади. ! 4. Вакцина TSLP для применения в медицине. ! 5. Способ получения вакцины по п.1, при котором клонируют кДНК или геномную последовательность TSLP или ее участок, кодирующий более чем 5 аминокислот, лигируют в подходящем векторе, трансформируют этим вектором эукариотическую или прокариотическую клетку-хозяина для продуцирования слитого белка, содержащего полноразмерную последовательность TSLP или ее участок в исходной, или в мутированной, или в мультимеризованной форме, и очищают и возможно смешивают полученный ...

MEDICAMENT FOR THE TREATMENT OF HERPES SIMPLEX

... 1379008 Herpes simplex vaccine MEDITEST-INSTITUT FUR MEDIZINISCH PHARMAZEUTISCHE UNTERSUCHUNGEN GmbH 29 March 1973 [30 March 1972] 15219/73 Heading A5B An oral vaccine for the treatment of Herpes simplex comprises Vaccinia Virus adsorbed on an inert substrate. The virus may be Elstree source Vaccinia Virus. It may be derived from calf skin. The substrate may be finely divided silica or a silicate. The preparation may also include urea to accelerate absorption in the intestine. The virus may be homogenized and adsorbed on the substrate and the composition centrifuged, freeze dried and made up into tablets. The tablets may be coated with polyvinyl alcohol or polyvinyl pyrrolidone.

Method for the preparation of a novel nanoparticle conjugate

INDUCTION of the ANSWERS of CYTOTOXIC t LYMPHOZYTEN

MUTANTEN FROM HÜLLGLYKOPROTEINEN HUMANLY IMMUNODEFICIENCY OF THE VIRUS AND THEIR USE

HIV EPITOPE AND THIS CONTAINING PHARMACEUTICAL COMPOSITION

COAGULATING FACTOR VII-FC CHIMÄRE PROTEINS FOR THE TREATMENT OF HÄMOSTATI DISEASES

Cd40 binding molecules and ctl peptides for treating tumors

CD40 binding molecules and CTL peptides for treating tumors

Circular CCR5 peptide conjugates and uses thereof

Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia

The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.

Nanoparticle compositions for sustained therapy

This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of T ...

FLUOROCARBON ANTIGEN DELIVERY VECTORS AND CONSTRUCTS

... ²²²The present invention relates to fluorocarbon vectors for the delivery of ²antigens to immunoresponsive target cells. It further relates to fluorocarbon ²vector-antigen constructs and the use of such vectors associated with antigens ²as vaccines and immunotherapeutics in animals.² ...

COMPOSITIONS COMPRISING SECRETED EXTRACELLULAR VESICLES OF CELLS EXPRESSING NFATC4 USEFUL FOR THE TREATMENT OF CANCER

The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin- dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGFß1 expression level.

T-CELL INDUCING VACCINE COMPOSITION COMBINATIONS AND USES THEREOF

Provided herein are vaccine combinations and methods for enhancing an antigen specific T cell induced response in a subject in need thereof. The methods combine systemic vaccination with a first composition containing a non-replicating viral vector encoding an antigen or immunogen containing one or more CD8+ T cell epitopes; and/or a second composition with micelles containing fluorocarbon-linked peptides, wherein each peptide linked to the fluorocarbon is: i) 15 to 75 amino acid residues long; ii) from the antigen or immunogen of the first composition; and, iii) contains one or more of the CD8+ T cell epitopes of the first composition from the antigen or immunogen to induce antigen specific CD8+ T cells; and optionally a third composition comprising an immune modulator composition.

METHODS AND COMPOSITIONS FOR TREATMENT WITH SYNTHETIC NANOCARRIERS AND IMMUNE CHECKPOINT INHIBITORS

Disclosed are synthetic nanocarrier compositions containing antigens and immunostimulators as well as immune checkpoint inhibitor compositions and related methods for administration to a subject.

DE-N-ACETYL SIALIC ACID ANTIGENS, ANTIBODIES THERETO, AND METHODS OF USE IN CANCER THERAPY

The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.

TSLP VACCINE FOR THE TREATMENT OF TH2 MEDIATED INFLAMMATORY CONDITIONS

The invention relates to compositions for the treatment of TH2 mediated i nflammatory conditions. The compositions are vaccines comprising a non-prima te TSLP or fragments thereof to be used as a vaccine to treat humans with ex cessive TH2 mediated inflammatory conditions. For the treatment of TH2 media te inflammatory conditions in other non-human mammals the TSLP of the specie s to be vaccinated is being used as antigen.

CIRCULAR CCR5 PEPTIDE CONJUGATES AND USES THEREOF

The present invention is in the fields of medicine, public health, immuno logy, molecular biologyand virology. The invention provides composition comp rising a virus-like particle (VLP) linked to atleast one antigen, wherein sa id antigen is CCR5 PNt domain comprising one looped peptidic structure. The invention also provides a process for producing the composition. The composi tions ofthis invention are useful in the production of vaccines, in particul ar, for the prevention and treatment of HIV infection. Moreover, the composi tions of the invention induce efficient immune responses, in particular anti body responses.

NON-AQUEOUS SYNTHESIS OF POLYSACCHARIDE-PROTEIN CONJUGATES FOR VACCINES

The invention is a novel chemical coupling methodology for the synthesis of a stable polysaccharide-protein conjugates as the immunogenic component for vaccines. A covalent bond is formed between polysaccharide and protein in the dry state in the absence of water and oxygen. A polysaccharide antigen is covalently linked to the protein by activating the polysaccharide with periodate to introduce aldehyde groups into the polysaccharide, lyophilizing an aqueous mixture of a protein and activated polysaccharide, sealing the dry lyophilized mixture in a vessel under vacuum or inert gas and then incubating the sealed vessel at an elevated temperature.

APPARATUS, SYSTEM, AND METHOD FOR CREATING IMMUNOLOGICALLY ENHANCED SPACES IN-VIVO

The present invention creates an immunologically protected/enhanced space in vivo in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within the body. Placing an antigen source within the defined protected space along with a monocyte-containing blood sample from the mammal being treated and a dendritic cell-inducing factor allows a dendritic-antigen presentation process to proceed to completion. The protected/enhanced space is created by surrounding the protected space with ligands which absorb and/or bind to one or more soluble inhibitors. The implant can be loaded with a patient's cancer cells to treat cancer.

METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine ("DMPC"); either dimyristoylphosphatidylglycerol ("DMPG") or dimyristoyltrimethylammonium propane ("DMTAP") or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).

SYNTHETIC NANOCARRIER COMBINATION VACCINES

Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.

VACCINES COMPRISING CHOLESTEROL AND CPG AS SOLE ADJUVANT-CARRIER MOLECULES

Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OFAUTOIMMUNE CONDITIONS

The methods include selectively reducing or expanding T cells according t o the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoan tigens, such as beta cell specific T cells. As such, the present invention c an be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimm une diseases.

RESPIRATORY SYNCYTIAL VIRUS ANTIGENIC COMPOSITIONS AND METHODS

Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response.

MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION, AND METHODS AND USES THEREOF

The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.

MICROPARTICULES BEARING ANTIGENS AND THEIR USE FOR THE INTRODUCTION OF HUMORAL AND CELL RESPONSES

Utilisation pour l'induction d'une réponse immunitaire de microparticules en matériau synthétique polymère portant en surface une ou plusieurs protéines liées de manière covalente pouvant porter un ou plusieurs épitopes, les densités de la ou des protéines à la surface des microparticules, ainsi que leurs poids moléculaires, étant ajustées afin d'orienter la réponse immunitaire vers l'induction d'une réponse humorale et cellulaire ou vers l'induction d'une réponse majoritairement cellulaire. Les microparticules ont un diamètre moyen compris entre environ 0,25 et environ 1,5 .mu.m.

METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

PREPARATION FTORUGLERODSVYaZANNYKh PEPTIDES

ВЕКТОРЫ И КОНСТРУКЦИИ ДЛЯ ДОСТАВКИ ГРИППОЗНОГО АНТИГЕНА

Изобретение относится к фторуглеродным векторам для доставки гриппозных антигенов к иммунологически реактивным клеткам-мишеням. Оно относится также к конструкциям "вектор-гриппозный антиген" и к применению указанных векторов, связанных с антигенами, в качестве вакцин и иммунотерапевтических агентов у животных, включая людей.

COMPOSITION NANOPARTICLE - PEPTIDE

IMPROVED TRANSPORT MOLECULES MODULAR ANTIGEN AND THEIR USE

NEW ENV SITE INSERTION ORF70

Respiratory Syncytial Virus Antigenic Compositions and Methods

Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response.

Vaccine

The present invention relates to a pharmaceutical formulation comprising lipopolysaccharide derived from Burkholderia thailandensis and its various uses, including but not limited to its use in the treatment and/or prophylaxis of meliodosis or amelioration of symptoms associated therewith, and/or glanders or amelioration of symptoms associated therewith.

Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof

The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.

Artificial cells

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Artificial cells

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Vaccine composition for prophylaxis and/or therapy of alzheimer's disease

A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.

Purified Plasmodium and Vaccine Compositions

Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.

Targeted multi-epitope dosage forms for induction of an immune response to antigens

Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.

Tat-Based Tolerogen Compositions and Methods for Making and Using Same

A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.

Continuous Cell Programming Devices

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Manufacture of vaccines that contain both hepatitis b virus surface antigens and surfactant

When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.

Compositions comprising angiogenic factors and methods of use thereof

The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.

Hiv cd4 binding site based covalent immunogen compositions

Provided are immunogenic compositions based on the highly conserved, core CD4 binding site of the gp120 protein of the human immunodeficiency virus. One embodiment includes an antigenic conjugate of an electophilic derivative of HIV gp120 peptide 416-433, designated E-416-433, covalently linked to an immunogenic carrier protein. The compositions are effective in stimulating the production of HIV neutralizing antibodies in mammals. Provided also are related methods of immunization, methods of antibody production and antibodies obtained using the methods of the invention.

Tat-Based Vaccine Compositions and Methods of Making and Using Same

A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based vaccine composition comprising immunostimulatory lentivirus Tat is provided.

Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines

Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis , as well as Yersina pestis . The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.

Molecular complexes which modify immune responses

Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.

Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof

An immunogenic product includes TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described.

Adjuvanting meningococcal factor h binding protein

Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

Antigen specific multi epitope-based anti-infective vaccines

Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.

Compositions and methods for treatment of cervical dysplasia

The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and an E7 and/or E6 antigen. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.

Lipid vesicle compositions and methods of use

The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally.

Polyethylene glycol-based dendrons

The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use.

Compositions and methods to treat and control tumors

The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that compromises a B cell and a T cell component.

Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines

The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.

Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Immunologically modified carbon nanotubes for cancer treatment

A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.

Protein matrix vaccines of improved immunogenicity

The present invention relates to immunogenic compositions containing an antigen of interest entrapped with a crosslinked carrier protein matrix, methods of making such vaccines, and methods of vaccine administration, wherein the immunogenicity of the protein matrix, and hence its effectiveness as a vaccine, is improved by controlling or selecting the particle size of the protein matrix particles to eliminate low molecular weight particles, e.g., less than 100 nm in diameter.

Vaccine for Modulating Between T1 and T2 Immune Responses

The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.

Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions

The present invention relates to immunogenic conjugates comprising S. aureus serotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carboyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).

Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use

Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens.

Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.

Tolerogenic synthetic nanocarriers

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Chemically programmable immunity

Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

Packaging of Immunostimulatory Substances into Virus-Like Particles: Method of Preparation and Use

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

Compositions and methods for treating airway inflammatory diseases

A composition for treating an airway inflammatory disease having high molecular weight, crosslinked hyaluronan and at least one aeroallergen is provided. A method of inducing immune tolerance to one or more aeroallergens in a mammalian subject suffering from or at risk of developing an airway inflammatory disease, and a method of treating a human subject suffering from or at risk of developing an airway inflammatory disease or condition of the lungs are also provided.

Immunogenic lhrh compositions and methods relating thereto

The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs.

Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins

A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.

Process for manufacturing vaccines

The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.

Immunogenic composition

Immunogenic compositions and methods of their use, as well as processes for their production are provided herein.

HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER

The present invention is directed to a vaccine and a pharmaceutical composition comprising hCG and Mycobacterium w suitable for administration to a subject in need thereof for the prevention and/or treatment of cancer. The compositions when administered to a subject in need thereof results in enhanced immunogenicity and prevention against cancer. Furthermore, the compositions of the present invention, when administered to a subject in need thereof, result in inhibition of tumor growth.

New composition and methods for treatment of autoimmune and allergic diseases

The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically, the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1-subunit of the cholera toxin (CTA1), a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit, the amino acids corresponding to the amino acid 7, arginine, and amino acid 187, cysteine, in the native CTA1 have been replaced.

Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells

The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.

Immunogenic composition

Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.

Chloroplasts engineered to express pharmaceutical proteins

Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.

Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules

Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.

Compositions for transfection of biomolecules into cells

The present invention is directed to new compositions that are described for the simultaneous, controlled dose delivery of a variety of biomolecules into phagocytic cells. Such a composition is a biologically active composition comprising: (1) at least one of the following biologically active components: (a) a nucleic acid or a derivative thereof; (b) a nucleoside, nucleotide, or a derivative of a nucleoside or nucleotide; (c) a peptide, protein, or a derivative of a peptide or protein; (d) a lipopolysaccharide or a derivative thereof; (e) a peptidoglycan or a derivative thereof; (f) a carbohydrate or a derivative thereof; (g) a lipid or a derivative thereof; (h) a lipopeptide or a derivative thereof; (i) a metal ion; (j) a thiol; (k) an antibiotic or a derivative thereof; (I) a vitamin or a derivative thereof; (m) a bioflavonoid or a derivative thereof; (n) an antioxidant or a derivative thereof; (o) an immune response modifier; (p) an antibody; (q) a biologically active nonmetal; (r) histamine or an antihistamine; and (s) a kinase inhibitor; and (2) at least one carrier effective to deliver the composition to a phagocytic cell such that the biologically active component is taken up by the phagocytic cell and influences its biological activity.

Recombinant tumor vaccine and method of producing such vaccine

The present disclosure provides tumor vaccines useful for preventing and treating tumors and cancers. The tumor vaccines may contain nucleic acids encoding for antigen presenting peptides, cytokines and other factors useful for preventing and treating tumors and cancers, or expression vectors or viruses containing such nucleic acids, or host cells containing such nucleic acids or expression vectors.

Vault Compositions for Immunization

Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.

Dendritic Cells Loaded With Heat Shocked Melanoma Cell Bodies

The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.

Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned above. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and/or the inventive pharmaceutical composition, adjuvant or vaccine in one or more parts of the kit.

Hapten-Carrier Conjugates and Uses Thereof

The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.

Adjuvanting meningococcal factor h binding protein

Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

Yersinia pestis antigens, vaccine compositions, and related methods

The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis . The present invention provides pharmaceutical compositions of such antigens and/or vaccines. The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection.

Constrained immunogenic compositions and uses therefor

A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV), Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response.

Soluble Forms of Hendra and Nipah Virus G Glycoprotein

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

Recombinant t-cell receptor ligands with covalently bound peptides

Disclosed herein are stable complexes including an MHC class I or MHC class II recombinant T cell receptor ligand RTL polypeptide covalently linked to an antigenic determinant by a disulfide bond. Also disclosed are methods of making such compositions and methods of use, for example to treat or inhibit a disorder, for example, an autoimmune disorder.

Immunogenic composition

The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 μg.

Synthetic immunogen useful for generating long lasting immunity and protection against pathogens

The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X 1 =a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X 2 =a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

Conjugates comprising an n-oxime bond and associated methods

Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R′ is derived from a compound comprising at least one reactive amide group, R″ is derived from a compound comprising at least one reactive aminooxy group, and X is H, C n H (n+2) or other atoms. Additional methods are also provided.

Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen

This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo.

Complex having tumor vaccine effect, and use thereof

The present invention provides a tumor cell-soluble TNF family member molecule complex containing a tumor cell and an isolated soluble TNF family member molecule, wherein the soluble TNF family member molecule is bound on a surface of the tumor cell such that it binds to a receptor of the TNF family member expressed on a surface of a cell other than the tumor cell, and stimulates the cell other than the tumor cell via the receptor, and a composition and a tumor vaccine, each containing the complex.

Methods of Making Hemagglutinin Proteins

Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. The protein portion includes at least a portion of a globular head, and at least a portion of at least one secondary structure having at least one β-sheet at a bottom of the globular head that causes the globular head to essentially retain its tertiary structure. The protein portion made by the methods of the invention lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. A nucleic acid sequence encoding the protein portion is transformed into a prokaryotic host cell.

Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection

Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

Vaccine composition

The present invention relates to DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided.

Epitopes of herpes simplex virus

The present invention relates to diagnosis, prevention and treatment of Herpes simplex viruses and infection. In particular embodiments the present invention relates to methods and compositions for the prophylactic or therapeutic immunization against of infections of HSV. The present invention also relates to methods and compositions for diagnosis of the presence of and level of immunity to HSV. The invention also relates to peptide epitopes of HSV, in particular peptide epitopes of HSV2 glycoprotein D, to compositions thereof and to the use of such epitopes and compositions in methods for diagnosis, prevention and treatment of HSV.

Antigen-norovirus p-domain monomers and dimers, antigen norovirus p-particle molecules, and methods for their making and use

A substituted Norovirus capsid protein monomer, having only the P-domain, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral, antigen-Norovirus P-particle, composed of 24 copies of the monomer. Each substituted P-domain monomer can contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus and as a carrier for development of vaccines against many infectious and non-infectious diseases. The substituted monomer can be readily produced in E. coli and yeast, are highly stable and tolerate a wide range of physio-chemical conditions. The P-particle-VP8 chimeras may also serve as a dual vaccine, for example, against both rotavirus and norovirus.

Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax

Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.

Dendritic Cell Marker and Uses Thereof

The present invention relates to the identification of proteins located on the cell surface of dendritic cells or precursors thereof, particularly antigen presenting dendritic cells. In particular, the present invention relates to compounds such as antibodies that bind these proteins. These compounds can be used to detect and/or enrich a subset of dendritic cells or precursors thereof. These compounds can also be used to target antigens to dendritic cells or precursors thereof to modulate a humoral and/or T cell mediated immune response to an antigen, or used to target cytotoxic agents to dendritic cells or precursors thereof involved in diseased states.

Dna vaccine against multitypes of avian influenza viruses and influenza virus-like particles comprising adjuvant-fused m2 protein

A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided

Conjugation of Streptococcal Capsular Saccharides

Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae . In the first method, reductive animation of oxidised sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.

Chimeric antigens for eliciting an immune response

Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases

Methods are disclosed for treating or inhibiting an autoimmune disease in a subject. In some embodiments, the disclosed methods include administering to the subject a therapeutically effective amount of one or more Major Histocompatibility Complex (MHC) molecules including covalently linked first, second and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen associated with the autoimmune disorder. The method also includes administering a therapeutically effective amount of one or more antibodies that bind to B cells, for example an antibody that specifically binds CD20. In specific non-limiting examples, the autoimmune disease is multiple sclerosis or rheumatoid arthritis.

Conjugated beta-1,3-linked glucans

Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation.

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Protein-binding peptide isolated from placenta growth factor

Embodiments of the invention are described, including materials and methods for making molecules and materials that have a specific binding domain of a PlGF2. Embodiments include, for instance, medicaments, biomaterials, biomolecules, molecular fusions, and vaccines.

Polyvalent conjugate vaccine for cancer

This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le y , Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.

Compositions and methods using recombinant mhc molecules for the treatment of stroke

Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.

Vaccine against streptococcus pneumoniae

The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.

Bi-specific conjugates

The present invention provides a conjugate comprising: i) at least one first specific binding molecule which binds CD40, wherein said first specific binding molecule is an agonist of CD40; and ii) at least one second specific binding molecule which binds a tag moiety, wherein said tag moiety is not a cancer antigen, wherein said first specific binding molecule and second specific binding molecule are antigen-binding proteins comprising an antigen-binding domain of an antibody and are covalently linked. The conjugate can be combined with a tag construct comprising: i) a tag moiety which is not a cancer antigen; and ii) an antigen, being a cancer antigen or an antigen derived from a pathogen; wherein said antigen is a polypeptide and said tag moiety is covalently linked to said antigen, for use in therapy, to stimulate an immune response by a subject against the antigen in question.

Methods and compositions for the treatment of hepatitis b infection

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

Polymer adjuvant

The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.

Compositions and Methods for the Production of Virus-Like Particles

Compositions and methods for synthesizing virus-like particles (VLPs) and methods of use thereof are provided.

Nanoparticle Delivery of TLR Agonists and Antigens

Compositions of one or more TLR agonists and one or more antigens adsorbed or attached to the same particles or to different particles are provided. Also provided are methods for producing and using these compositions. 1. A composition comprising one or more TLR agonists , one or more antigens and a first plurality of particles to which the one or more TLR agonists and one or more antigens are attached , said one or more antigens and said one or more TLR agonists being at a ratio which increases immunogenicity to the one or more antigens and/or decreases reactogenicity to the one or more TLR agonists.2. The composition of wherein the one or more TLR agonists and one or more antigens are both attached to the first plurality of particles.3. The composition of further comprising a second plurality of particles wherein the one or more TLR agonists are attached to the first plurality of particles and the one or more antigens are attached to the second plurality of particles.4. The composition of wherein the particles are comprised of a lipid.5. The composition of wherein the lipid is selected from the group consisting of Dynasan118/PEG35-castor oil blend claim 4 , natural Carnauba wax claim 4 , synthetic carnauba wax claim 4 , Bees wax claim 4 , a self-emulsifying wax claim 4 , polyethylene wax claim 4 , behenyl alcohol and oleic acid/compritol.6. The composition of wherein the lipid is carnauba wax.7. The composition of wherein the carnauba wax comprises aliphatic esters claim 6 , diesters of 4-hydroxycinnamic acid ω-hydroxycarboxylic acids and fatty acid alcohols.8. The composition of wherein the ratio of the TLR agonist to antigen is less than about 1:5 on a weight to weight basis.9. The composition of wherein the ratio of the TLR agonist to antigen is less than about 1:20 on a molecule to molecule basis.10. The composition of further comprising a surfactant.11. The composition of wherein the surfactant is selected from the group consisting of cetyl triammonium ...

SYNTHETIC CONJUGATE OF CpG DNA AND T-HELP/CTL PEPTIDE

Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide. 1. A method of increasing the effectiveness of an antigenic peptide CTL epitope vaccine component which comprises conjugating said antigenic peptide CTL epitope to a DNA oligomer , wherein said peptide is selected from the group consisting of SEQ ID NOs:1-6.2. The method of claim 1 , wherein said DNA oligomer comprises a CpG sequence.3. The method of claim 2 , wherein said DNA oligomer is a phosphodiester CpG DNA.4. The method of claim 2 , wherein said DNA oligomer is a fully phosphorothioated backbone CpG DNA.5. The method of claim 1 , wherein said DNA oligomer comprises about 8 to about 300 nucleotide bases.6. The method of claim 5 , wherein said DNA oligomer comprises about 15 to about 100 nucleotide bases.7. The method of claim 5 , wherein said DNA oligomer comprises about 20 to about 25 nucleotide bases.8. The method of claim 1 , wherein said peptide is selected from the group consisting of SEQ ID NOs:1-4.9. The method of claim 1 , wherein said antigenic CTL peptide is a fusion peptide comprising a T-help epitope and said CTL peptide.10. The method of claim 10 , wherein said T-help epitope is SEQ ID NO:12.11. The method of claim 1 , wherein said antigenic peptide is synthetic.12. A conjugated vaccine molecule which comprises an antigenic peptide CTL epitope covalently attached to a DNA oligomer claim 1 , wherein said peptide is selected from the group consisting of SEQ ID NOs:5 and 6.13. The molecule of claim 12 , wherein said DNA oligomer comprises a CpG sequence.14. The molecule of claim 13 , wherein said DNA oligomer is a phosphodiester CpG DNA.15. The ...

VACCINE COMPOSITIONS AND METHODS FOR RESTORING NKG2D PATHWAY FUNCTION AGAINST CANCERS

The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide. 1. A vaccine composition for treating cancer , the composition comprising , as an immunogenic component , an effective amount of a peptide comprising or consisting of one or more of SEQ ID NOs: 1-13 , the effective amount being an amount effective to elicit an immune response against a MIC polypeptide , or the cancer.2. The vaccine composition of claim 1 , wherein the composition is effective to elicit an in vitro immune response against a MIC polypeptide.3. The vaccine composition of claim 1 , wherein the composition is effective to elicit an in vivo immune response against a MIC polypeptide.4. The vaccine composition of claim 1 , wherein the MIC polypeptide is not attached to a cell.5. The vaccine composition of claim 1 , wherein the composition is effective to elicit an immune response against a cancer cell expressing a MIC polypeptide.6. The vaccine composition of claim 1 , wherein the MIC polypeptide is a MICA or MICB polypeptide.7. The vaccine composition of claim 1 , wherein the cancer expresses MICA and/or MICB proteins.8. The vaccine composition of claim 1 , wherein the cancer is melanoma.9. The vaccine composition of claim 1 , wherein the peptide comprises or consists of one or more of SEQ ID NOs 2-13 claim 1 , or SEQ ID NOs: 15-23 claim 1 , or a peptide having 90% or 95% amino acid sequence identity to any of the same.10. The vaccine composition of claim 1 , wherein the vaccine composition comprises a plurality of peptides selected from two or more of SEQ ID NOs 5-10 claim 1 , or SEQ ID NOs: 15-20 or a peptide having 95% amino acid sequence identity to any of the same; or from two or more of SEQ ID NOs 2-13 claim 1 , or SEQ ID NOs: 21-23 or a peptide having 90% amino acid sequence identity to any of the same.11. The vaccine composition of claim 1 , wherein the peptide is conjugated to a carrier protein.12. The ...

COMBINATION THERAPY FOR IMMUNOSTIMULATION

The present invention relates to a method for immunostimulation in a mammal which comprises a. administration of at least one mRNA containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. administration of at least one cytokine, at least one cytokine mRNA, at least one CpG DNA or at least one adjuvant RNA. The invention likewise relates to a product and a kit comprising the mRNA and cytokine or cytokine mRNA or CpG DNA or adjuvant RNA of the invention. 1. A method of stimulating an antitumor immune response in a subject comprising administering an effective amount of a cell-free composition comprising mRNA encoding an Survivin antigen to a subject in need thereof , thereby stimulating a T-cell mediated cytotoxic anticancer immune response in the subject.2. The method of claim 1 , wherein the subject has a cancer.3. The method of claim 2 , wherein the cancer is a lung cancer.4. The method of claim 1 , wherein the composition comprises mRNA encoding at least 2 claim 1 , 3 claim 1 , 4 or 5 different tumor antigens.5. The method of claim 1 , wherein the method further comprises administering at least 2 claim 1 , 3 claim 1 , 4 or 5 different cell-free compositions comprising mRNA encoding different tumor antigens to the subject.6. The method of claim 1 , wherein the mRNA is complexed with as least one cationic or polyocationic agent.7. The method of claim 6 , wherein the cationic or polyocationic agent is chosen from the group consisting of protamine claim 6 , poly-L-lysine claim 6 , poly-L-arginine and histones.8. The method of claim 7 , wherein the mRNA is complexed with protamine.9. The method of claim 1 , further comprising administering one or more adjuvant(s) to the subject.10. The method of claim 9 , wherein the adjuvant is chosen from the group consisting of lipopolysaccharide claim 9 , TNF-α claim 9 , CD40 ligand claim 9 , GP96 claim 9 , oligonucleotides with a CpG motif claim 9 , aluminum hydroxide claim 9 , ...

Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an anti-HSP70 monoclonal antibody, conferring specific immunity against HSP70 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating in particular leukemia.

ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. 158.-. (canceled)59. A method for inducing cytotoxic T-cell response against tumor cells in a subject in need thereof , the method comprising administering to the subject an effective amount of a composition comprising a fusion protein , wherein the fusion protein comprises an anti-CD40 antibody or portion thereof linked to one or more cancer antigens.60. The method of claim 59 , wherein the cancer antigens are selected from tumor associated antigens selected from CEA claim 59 , prostate specific antigen (PSA) claim 59 , HER-2/neu claim 59 , BAGE claim 59 , GAGE claim 59 , MAGE 1-4 claim 59 , 6 and 12 claim 59 , MUC (Mucin) (e.g. claim 59 , MUC-1 claim 59 , MUC-2 claim 59 , etc.) claim 59 , GM2 and GD2 gangliosides claim 59 , ras claim 59 , myc claim 59 , tyrosinase claim 59 , MART (melanoma antigen) claim 59 , MARCO-MART claim 59 , cyclin B1 claim 59 , cyclin D1 claim 59 , Pmel 17(100) claim 59 , GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence) claim 59 , Prostate Ca psm claim 59 , prostate serum antigen (PSA) claim 59 , PRAME (melanoma antigen) claim 59 , β-catenin claim 59 , MUM-1-B (melanoma ubiquitous mutated gene product) claim 59 , GAGE (melanoma antigen) 1 claim 59 , BAGE (melanoma antigen) 2-10 claim 59 , c-ERB2 (Her2/neu) claim 59 , EBNA (Epstein-Barr Virus nuclear antigen) 1-6 claim 59 , gp75 claim 59 , human papilloma virus (HPV) E6 and E7 claim 59 , p53 claim 59 , lung resistance protein (LRP) claim 59 , Bcl-2 claim 59 , survivin claim 59 , and Ki-67.61. The method of claim 60 , wherein the tumor antigen ...

TOXOID PREPARATION AND USES THEREOF

The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines. 1. A toxoid preparation , comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin , provided that said toxoid preparation does not comprise a nanoparticle comprising an inner core comprising a non-cellular material , and an outer surface comprising a cellular membrane derived from a cell and a cell membrane inserting toxin , wherein said cell membrane inserting toxin is associated with said cellular membrane without a linker.2. The toxoid preparation of claim 1 , wherein the toxin is selected from the group consisting of a pore-forming toxin claim 1 , an inhibitory toxin claim 1 , a toxin interacts with a cellular receptor or secondary messenger to disrupt normal cellular metabolism claim 1 , a neurotoxin claim 1 , and an enterotoxin.35-. (canceled)6. The toxoid preparation of claim 1 , wherein the toxin is associated with the particulate vector via encapsulation claim 1 , electrostatic absorption claim 1 , non-specific interaction claim 1 , and/or structure-specific association.7. The toxoid preparation of claim 1 , wherein the particulate vector is configured to facilitate endocytic uptake of the toxoid preparation and/or minimizes premature toxin release from the toxoid preparation.8. (canceled)9. The toxoid preparation of claim 1 , which comprises a lipoplex comprising synthetic lipid bilayers and an absorbed membrane-affinity toxin.1012-. (canceled)13. The toxoid preparation of claim 1 , which ...

NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human. 1Neisseria meningitidisNeisseria meningitidisN. meningitidisN. meningitidisNeisseria meningitidisNeisseria meningitidisNeisseria meningitidisNeisseria meningitidis. A method for inducing a bactericidal immune response against a serogroup B subfamily A strain , and against a serogroup B subfamily B strain in a human , comprising concomitantly administering an effective amount of a rLP2086 composition and at least one additional immunogenic composition , wherein said rLP2086 composition comprises a) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 , and b) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2; wherein the at least one additional immunogenic composition comprises: (i) an immunogenic composition against a serogroup A strain , a serogroup C strain , a serogroup Y strain , and/or a serogroup W135 strain; (ii) an immunogenic composition against diphtheria , tetanus , and pertussis; (iii) an immunogenic composition against hepatitis A virus; (iv) an immunogenic composition against human papillomavirus; (v) an ...

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF

The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker. 1. An isolated , modified peptidoglycan comprising at least one modified D-amino acid comprising a bioorthogonal group.2. An isolated , modified peptidoglycan comprising at least one modified D-amino acid chemically conjugated to a reagent via a heterocycle , wherein the modified D-amino acid is an azide-modified , an alkyne-modified , or a norbornene-modified D-amino acid , and the reagent is an azide-containing reagent , an alkynyl reagent or a norbornene-reactive reagent.3. The isolated claim 2 , modified PG of claim 2 , wherein the reagent comprises a detectable label.4. The isolated claim 2 , modified PG of claim 2 , wherein the reagent comprises a therapeutic agent.5. The isolated claim 2 , modified PG of claim 2 , wherein the reagent comprises an immunomodulatory molecule.6. A modified bacterial cell comprising a modified peptidoglycan claim 2 , wherein the modified peptidoglycan comprises at least one modified D-amino acid claim 2 , wherein the at least one modified D-amino acid is an azide-modified claim 2 , an alkyne-modified claim 2 , or a norbornene-modified D-amino acid.7. A method of identifying an agent that inhibits peptidoglycan synthesis claim 2 , the method comprising:a) contacting a bacterial cell in vitro with a test agent; andb) determining the effect, if any, of the test agent on incorporation of a modified D-amino acid into peptidoglycan in the bacterial cell;wherein a test agent that inhibits incorporation of the modified D-amino acid into peptidoglycan in the bacterial cell is considered a candidate ...

HEAT SHOCK PROTEIN-BINDING PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions. 1. An isolated polypeptide comprising a heat shock protein (HSP)-binding peptide comprising the amino acid sequence of XLXLTX(SEQ ID NO: 1) , wherein Xis W or F; Xis R or K; and Xis W , F , or G.2. The isolated polypeptide of claim 1 , wherein the HSP-binding peptide comprises the amino acid sequence of:{'sub': 1', '2', '3', '1', '2', '3, '(a) NXLXLTX(SEQ ID NO: 2), wherein Xis W or F; Xis R or K; and Xis W, F, or G;'}{'sub': 1', '2', '1', '2, '(b) WLXLTX(SEQ ID NO: 3), wherein Xis R or K; and Xis W or G; or'}{'sub': 1', '2', '1', '2, '(c) NWLXLTX(SEQ ID NO: 4), wherein Xis R or K; and Xis W or G.'}3. The isolated polypeptide of claim 1 , wherein:(a) the HSP-binding peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-12, 98-113, 207, and 212;(b) the amino acid sequence of the HSP-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-12, 98-113, 207, and 212:(c) the HSP-binding peptide comprises the amino acid sequence of SEQ ID NO: 6; and/or(d) the amino acid sequence of the HSP-binding peptide consists of the amino acid sequence of SEQ ID NO: 6.46-. (canceled)7. An isolated polypeptide comprising an HSP-binding peptide comprising the amino acid sequence of NWXXXXX(SEQ ID NO: 232) claim 1 , wherein Xis L or I; Xis L claim 1 , R claim 1 , or K; Xis L or I; Xis T claim 1 , L claim 1 , F claim 1 , K claim 1 , R claim 1 , or W; and Xis W or K.8. The isolated polypeptide of claim 7 , wherein the HSP-binding peptide comprises an ...

IMMUNOGENIC COMPOSITION

The present application discloses an immunogenic composition comprising at least 2 different capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s). 1106.-. (canceled)107. An immunogenic composition , comprising:{'i': Neisseria meningitidis', 'N. meningitids, '(a) a () serogroup A capsular saccharide conjugated to an adipic acid dihydrazide (ADH) linker, wherein the linker is conjugated to tetanus toxoid carrier protein;'}{'i': 'N. meningitidis', '(b) a serogroup C capsular saccharide conjugated to an adipic acid dihydrazide (ADH) linker, wherein the linker is conjugated to tetanus toxoid carrier protein;'}{'i': 'N. meningitidis', '(c) a serogroup W capsular saccharide directly conjugated to tetanus toxoid carrier protein in the absence of a linker; and'}{'i': 'N. meningitidis', '(d) a serogroup Y capsular saccharide directly conjugated to tetanus toxoid carrier protein in the absence of a linker;'}{'i': 'N. meningitidis', 'wherein each capsular saccharide is present at a dose of 5 μg.'}108. The immunogenic composition of claim 107 , wherein the ratio of Men W and/or Y saccharide to carrier protein is between 1:0.5 and 1:2 (w/w).109. The immunogenic composition of claim 107 , wherein the composition does not include an adjuvant.110. The immunogenic composition of claim 107 , wherein the composition does not include an aluminum salt adjuvant.111. The immunogenic composition of claim 107 , further comprising sucrose.112N. meningitidis. The immunogenic composition of claim 107 , further comprising a serogroup B outer membrane vesicle preparation or capsular saccharide.113HaemophilusH. influenzaeH. influenzae. The immunogenic composition of claim 107 , further comprising ...

IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES

An object of the present invention is to provide immunogenic compositions for protection against , in particular against serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions. 1S. pneumoniae. An immunogenic composition comprising at least one glycoconjugate from serotype 39.2. The immunogenic composition of wherein claim 1 , said serotype 39 glycoconjugate has a molecular weight of between 50 kDa and 30 claim 1 ,000 kDa.3. The immunogenic composition of any one of - wherein claim 1 , said serotype 39 glycoconjugate comprises a saccharide which has a degree of O-acetylation of between 10 and 100%.4. The immunogenic composition of any one of - wherein said serotype 39 glycoconjugate comprises at least 0.01 O-acetyl group per polysaccharide repeating unit of serotype 39 polysaccharide.5. The immunogenic composition of any one of - wherein the degree of conjugation of said serotype 39 glycoconjugate is between 2 and 19.6. The immunogenic composition of any one of - wherein claim 1 , the ratio (w/w) of serotype 39 capsular saccharide to carrier protein in serotype 39 glycoconjugate is between 0.5 and 3.7. The immunogenic composition of any one of - wherein at least 30% of the serotype 39 glycoconjugates have a Kbelow or equal to 0.3 in a CL-4B column.8Haemophilus influenzae. The immunogenic composition of any one of - wherein the carrier protein of said serotype 39 glycoconjugate is selected from the group consisting of: DT (Diphtheria toxin) claim 1 , TT (tetanus toxid) claim 1 , CRM claim 1 , other DT mutants claim 1 , PD (protein D) claim 1 , or immunologically functional equivalents thereof.9S. pneumoniaeS. pneumoniaeS. pneumoniae. An immunogenic composition comprising at least one glycoconjugate from serotype 10A ...

Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

THERMALLY STABLE ROTAVIRUS VACCINE FORMULATIONS AND METHODS OF USE THEREOF

The present invention relates to thermally stable oral rotavirus vaccine formulations comprising one or more rotavirus reassortant or attenuated rotavirus strains, a pharmaceutically acceptable calcium salt, adipic acid, sucrose, and sodium phosphate, wherein each of the one or more rotavirus reassortant or attenuated rotavirus strain is stable for 7 days at 37° C., for 45 days at 25° C. and for 2 years or more at 2-8° C. The calcium containing formulations of the invention may further comprise one or more excipients which are present in an amount that is effective to optimize the calcium ions free in solution to stabilize the rotavirus particles. In embodiments of the invention, the formulation comprises a surfactant, such as polysorbate 80. The invention also relates to methods of using the rotavirus vaccine compositions of the invention to prevent rotavirus infection, or to reduce the likelihood of infection or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof. 1. A liquid rotavirus vaccine formulation comprising a pharmaceutically effective amount of at least one rotavirus reassortant or attenuated rotavirus strain , from about 1.0 mM to about 3.5 mM of a pharmaceutically acceptable salt of calcium , from about 0.5 M to about 2.0 M sucrose , from about 260 mM to about 700 mM adipic acid , and from about 10 mM to about 100 mM sodium phosphate; wherein the pH of the formulation is from about 6.2 to about 6.7.2. The rotavirus vaccine formulation of claim 1 , wherein the calcium is from calcium chloride.3. The rotavirus vaccine formulation of claim 1 , further comprising a non-ionic surfactant.4. The rotavirus vaccine formulation of claim 3 , wherein the non-ionic surfactant is polysorbate 80 claim 3 , which is present in a concentration of 0.008% to 0.04% w/v.5. The rotavirus vaccine formulation of claim 1 , wherein the formulation comprises one or more rotavirus reassortants selected from the group consisting of: G1 ...

Her1 antigen binding proteins binding to the beta-hairpin of her1

The invention relates to anti-HER1 antigen binding proteins, e.g. anti-HER1 antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament.